Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic and Wegovy. The company also turned to an insider to be its next CEO. Novo ...

TAMPA, FL / ACCESS Newswire / July 29, 2025 / The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, ...

TAMPA, FL / ACCESS Newswire / July 29, 2025 / The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, ...

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 s ...

The overarching commonality is that there isn't one: "Not all people experiences the same degree of facial and body changes ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

From supplements to injectables to belly-fat blasting beverages, there are plenty of products that claim to speed weight loss ...

The NSE Nifty 50 ended 0.63% higher at 25,219.90, while the BSE Sensex closed 0.66% up at 82,726.64 on Wednesday.

According to Research by SNS Insider, The U.S. GLP-1 Receptor Agonist Market to Reach USD 113.13 Billion by 2032, Driven by Rising Prevalence of Type 2 Diabetes and Demand for Obesity-Related ...

Wraparound care for patients taking GLP-1 agonists must include assessment of nutritional status to identify the risk of malnutrition, writes Ellen Fallows Food insecurity is increasing, particularly ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older adults. A small study found that up to 40% of weight loss from ...

- The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of ultra-long-acting subcutaneously ...